How to Choose a CPAP Machine

A procurement guide for DME suppliers, sleep centers, SNFs, and hospital home-health programs navigating a post-recall market.

---

What this is and who buys it

Continuous Positive Airway Pressure (CPAP) machines are FDA Class II prescription medical devices — classified under 21 CFR 868.5273 — that deliver a continuous pressurized airflow through a mask interface to maintain upper-airway patency during sleep. They are the front-line treatment for obstructive sleep apnea (OSA), a condition affecting an estimated 30 million adults in the United States. The therapeutic pressure range runs from 4 to 20 cmH₂O, delivered either at a fixed clinician-set level or auto-adjusted breath-by-breath depending on the device modality prescribed.

The buyers of CPAP equipment in bulk are rarely individual patients. Durable medical equipment (DME) suppliers, hospital home-health and sleep medicine programs, skilled nursing facilities (SNFs), and ambulatory sleep centers are the primary procurement entities. For DME providers, CPAP is a high-volume recurring revenue category billed under Medicare HCPCS E0601 as a 13-month rental-to-purchase cycle. For health systems, it often appears in the context of launching or scaling a hospital-based DME program or replacing an aging fleet on a 5–7 year replacement cycle.

The procurement landscape shifted dramatically between 2021 and 2024 following the Philips Respironics Class I recall — the most serious FDA recall classification — which removed approximately 15 million devices from service due to PE-PUR sound abatement foam degradation. A federal consent decree entered in April 2024 permanently barred Philips from selling new CPAP and BiPAP devices in the U.S. [S2] That event compressed a previously three-player market into effectively two dominant manufacturers and created both a supply gap and a used-device risk that any current procurement process must explicitly address.

---

Key decision factors

Device type and pressure modality is the first decision, and it should be driven by the prescribing clinician — not by procurement convenience. Fixed CPAP delivers one constant pressure throughout the night and is the simplest and lowest-cost modality. APAP (auto-titrating PAP) adjusts pressure within a prescribed range on a breath-by-breath basis, which is useful for patients whose pressure needs fluctuate or who haven't completed formal in-lab titration. BiPAP sets separate inspiratory and expiratory pressures for patients with complex or central components to their apnea, and ASV (Adaptive Servo-Ventilation) targets minute ventilation for mixed or purely central sleep apnea — a distinct clinical population. Each modality carries its own 510(k) lineage and a meaningfully different wholesale price tier.

Integrated humidification matters more for adherence than it might initially appear. Built-in heated humidifiers reduce condensation in the delivery tube (a phenomenon called "rainout") and are associated with higher long-term patient compliance. The key procurement question is whether the humidifier chamber is a replaceable consumable — which it should be — and whether your DME supply chain stocks it at 6-month replacement intervals. Add-on external humidifiers cost approximately $20–$50 per unit but introduce an additional inventory SKU and a potential failure point, which complicates fleet management at scale.

Wireless compliance data and HIPAA posture have become inseparable from CPAP procurement. Modern connected devices transmit nightly AHI (apnea-hypopnea index), usage hours, and leak rate to manufacturer cloud platforms. Under HIPAA, this data constitutes protected health information (PHI). Before any fleet deployment, you must have a signed Business Associate Agreement (BAA) from the manufacturer's cloud platform — and from any downstream analytics or billing software that ingests the data. This isn't a formality: a fleet-wide compliance data breach would trigger HITECH notification requirements. Also confirm upfront whether the embedded SIM and cellular data plan are included in device cost or billed separately.

Noise output is a direct adherence driver that is easy to overlook in spec-sheet comparisons. The accepted clinical engineering threshold is ≤30 dBA measured at one meter; some current-generation devices are rated as low as 26–27 dBA. When comparing vendor specs, insist on results from ISO 3745 or an equivalent standardized acoustic test methodology — not a marketing figure. A device that runs at 33–35 dBA may technically pass internal thresholds while meaningfully increasing patient non-compliance rates across a large fleet.

Pressure accuracy should be specified contractually. ISO 80601-2-70 is the device-specific performance standard governing sleep apnea breathing therapy equipment and is the standard manufacturers are expected to cite in their FDA 510(k) submissions. The accepted accuracy benchmark is ±0.5 cmH₂O across the full therapeutic range. Deviations outside this window — even if within CE-mark tolerances from a European submission — may not meet the therapeutic targets set by prescribing sleep physicians, which creates both clinical and liability exposure.

Supply chain stability is now a first-order procurement risk in this category. With Philips out of the new-device market, the CPAP supply chain is highly concentrated. Any vendor you select should be able to commit in writing to a minimum 5-year parts availability horizon for blower motors, PCBs, humidifier chambers, and filters. Verbal assurances are insufficient; build this commitment as a contractual clause with defined remedies if parts are discontinued before the agreed horizon.

IEC 60601-1-11 home-environment certification is a requirement many buyers underestimate. Home-use CPAP must comply with both IEC 60601-1 (general electrical safety) and the collateral standard IEC 60601-1-11 (home healthcare environment), which imposes additional EMC, installation, and usability requirements specific to uncontrolled home settings. Confirm that the certificate of compliance explicitly names IEC 60601-1-11 Ed. 2.0:2015 — not just the base standard. A device certified only to IEC 60601-1 may not satisfy FDA's special controls for home-use PAP devices [S1].

---

What it costs

List pricing for CPAP equipment varies significantly by modality, connectivity tier, and whether humidification is integrated. The ranges below reflect typical new-device pricing in the current U.S. market; actual acquisition cost through a GPO contract (Vizient, HealthTrust) or volume purchasing agreement can run 10–20% below list. Note that pricing for specific models is not publicly verified in granular detail by manufacturers; these bands represent market-level guidance.

• Entry tier ($250–$500): Fixed-pressure CPAP units with basic LCD displays and limited or no wireless telemetry. Suitable for straightforward OSA patients in programs where compliance monitoring is handled manually or by a separate device. Shorter warranty terms are common.
• Mid tier ($700–$1,100): APAP devices with integrated heated humidifiers, full cellular telemetry, and manufacturer compliance dashboard access. This is the primary fleet workhorse tier for most DME programs and represents the best balance of clinical utility and per-unit cost.
• Premium tier ($1,200+): BiPAP, ASV, and high-acuity APAP devices with advanced algorithms, enhanced data outputs, and extended warranties. These are appropriate for complex sleep apnea populations, SNF respiratory programs, and sleep center titration suites — not for undifferentiated DME fleet deployment.

---

Common use cases

CPAP procurement spans several distinct clinical and operational contexts, and the right device specification differs meaningfully across them.

• Home DME fleet deployment: The highest-volume use case. DME providers procure APAP or fixed CPAP in volume for OSA patients; compliance-reporting platform integration with billing software (e.g., Brightree, CPR+) is a critical requirement to support CMS HCPCS E0601 billing workflows without manual data entry.
• Sleep center in-lab titration: Devices used for split-night auto-titration studies must support pressure data export for physician review; connectivity and reporting format compatibility with the center's sleep scoring software is the primary technical requirement here.
• SNF and long-term care programs: Residents with diagnosed OSA require durable APAP or BiPAP units with straightforward staff-operable interfaces, low-maintenance filter schedules, and robust device construction — patient self-management is limited in this setting.
• Hospital home-health step-down and telehealth RPM: Patients discharged with new CPAP prescriptions need same-day or next-day DME delivery and compatible connected devices for remote patient monitoring; nightly AHI and usage data support CPT 99453–99457 RPM billing for qualifying programs.

---

Regulatory and compliance

CPAP devices are cleared as FDA Class II medical devices under 21 CFR 868.5273, reclassified from Class III via De Novo pathway (DEN170089), effective October 2018 [S1]. Clearance requires a 510(k) premarket notification and the device is prescription-only under 21 CFR 801.109. When evaluating 510(k) submissions, note that IEC 60601-1:2005/AMD2:2020 became mandatory for new FDA submittals as of December 17, 2023 — devices cleared after that date should reference the AMD2 version. Special controls under 868.5273 require biocompatibility testing for patient-contacting components, non-clinical performance testing simulating breathing across the intended pressure range, and specific labeling disclosures.

The Philips Respironics situation deserves separate attention as an active regulatory event. The FDA Class I recall covers approximately 15 million devices manufactured between 2009 and April 26, 2021, across all Philips CPAP, BiPAP, and ventilator models affected by PE-PUR foam degradation [S2]. The April 2024 federal consent decree bars Philips from selling new devices in the U.S. market. Any refurbished or used Philips unit — regardless of cosmetic condition or prior service records — must be verified against the FDA recall database at accessdata.fda.gov by serial number before it can be procured or redeployed. On the HIPAA front, DME accreditation bodies including The Joint Commission, ACHC, and CHAP require documented equipment inspection schedules; there is no mandatory regulatory calibration interval, but annual preventive maintenance is the manufacturer-standard recommendation.

---

Service, training, and total cost of ownership

Initial setup for home-use CPAP does not require clinical installation in a hospital sense, but patient setup — mask fitting, pressure ramp confirmation, and humidity settings — should be performed by a registered respiratory therapist (RRT) or credentialed sleep technologist. For fleet programs, vendor onboarding should include structured staff training on the compliance dashboard platform rather than informal "train the trainer" arrangements, which tend to degrade over time.

Consumable costs add up quickly at fleet scale. Disposable fine filters run approximately $5 per unit per month; reusable foam pre-filters require washing every two weeks. Humidifier chambers should be replaced every six months ($20–$50 per unit). Standard tubing turns every three months ($5–$35), while heated tubing runs $30–$75 per replacement. Mask cushions need replacement every one to three months, with full mask and headgear sets every six to twelve months at $50–$200 per set. In aggregate, annual consumable costs per patient range from approximately $220 at the low end to $1,600 for patients using heated tubing and higher-cost mask systems — a figure that should be built into any fleet financial model.

The expected service life for modern APAP devices is a minimum of five years, with the blower motor being the primary wear component. Most DME operators use a five-year fleet replacement cycle as a standard practice. When evaluating service contracts, the critical variable is whether the manufacturer provides a loaner device during depot repair: a gap in therapy has both clinical consequences and CMS compliance implications, since a patient who falls below the ≥4 hours/night on ≥70% of nights threshold during a repair window may lose coverage eligibility. Confirm loaner availability in writing before contract execution.

---

Red flags to watch for

Any Philips Respironics device manufactured before April 26, 2021, should be treated as presumptively recalled until serial-number verification confirms otherwise through the FDA database — this includes units offered at attractive prices through secondary markets or broker channels. The risk is not theoretical; recalled foam can degrade into carcinogenic particulates.

A device offered without a visible FDA 510(k) clearance number on its labeling is a disqualifying defect. All U.S.-marketed CPAP equipment is required to display this number; its absence is a violation of 21 CFR Part 801 and signals either an unapproved device or labeling so non-compliant that downstream warranty and liability protections are unreliable.

Vendors bundling ozone- or UV-based cleaning devices as "FDA-approved" CPAP cleaning solutions are misrepresenting regulatory status. As of 2024, the FDA has not granted marketing authorization for any ozone-based CPAP cleaning device; procurement packages that include these accessories should be treated with significant skepticism.

Finally, any cloud-connected CPAP vendor that declines to execute a Business Associate Agreement should be disqualified outright. The compliance data transmitted by these devices is PHI by definition; operating without a BAA creates direct HIPAA liability for the procuring organization, regardless of the strength of any other contractual language.

---

Questions to ask vendors

1. Provide the full FDA 510(k) clearance number and CDRH decision summary for this exact model and SKU. Is the device currently listed in any active FDA recall, correction, or removal action?
2. Which specific editions of IEC 60601-1, IEC 60601-1-11, IEC 60601-1-2, and ISO 80601-2-70 does this device comply with — and can you supply the accredited test certificates, not just a declaration of conformity?
3. Describe the telemetry architecture in full: what data is transmitted nightly, to which cloud platform, in which geographic data center, and will you execute a HIPAA Business Associate Agreement covering all downstream analytics sub-processors?
4. What is the clinically verified pressure accuracy across the full 4–20 cmH₂O range, under what test methodology, and can you provide the bench-test report rather than the marketing specification sheet?
5. Confirm in writing that no component of this device — flow generator, humidifier, mask interface — is subject to the Philips Respironics 2021 Class I recall or any subsequent FDA correction or removal action.
6. What is your committed U.S. parts availability horizon for this model's consumables (filters, humidifier chambers, heated tubing, blower assemblies), and what contractual remedies apply if parts are discontinued before five years?

---

Alternatives

The refurbished-versus-new decision carries more complexity in CPAP procurement than in most equipment categories, primarily because of the Philips recall's effect on used inventory. The reliable refurbished supply pool has contracted significantly since 2021; any used PAP device — regardless of source — requires mandatory serial-number recall verification before acceptance. Accredited DME resellers offering certified refurbished units typically discount 20–40% below new list price, but warranties are commonly 90 days versus two years for new equipment. For fleet programs, the liability and compliance audit exposure associated with refurbished units generally favors new procurement.

On financing structure, Medicare Part B covers CPAP under a 13-month rental-to-purchase model at approximately $107–$127 per month (Medicare allowable), after which ownership transfers to the patient. This model preserves capital for DME providers but requires the device to remain on their books for the rental period and demands a compliant billing workflow. Cash-pay programs serving uninsured patients are often better structured as direct purchase at the mid-tier price band. Health systems and larger DME operators should evaluate GPO contracts through organizations such as Vizient or HealthTrust, which can reduce new-device acquisition cost 10–20% versus standard list pricing.

For organizations debating whether to operate an in-house DME program versus contracting with a third-party DME supplier, the break-even typically requires more than approximately 200 new CPAP prescriptions per year to justify the billing infrastructure, CMS compliance monitoring software, and at minimum one RRT FTE. Below that threshold, a third-party DME arrangement preserves clinical staff bandwidth and eliminates accreditation overhead — at the cost of surrendering DME margin and some device-selection control. Finally, consider the fleet standardization argument for APAP over fixed CPAP: the $100–$200 per-unit premium buys pressure flexibility that eliminates re-titration events when prescriptions change, reducing SKU count and simplifying inventory management across large operations.

---

Sources

• FDA Federal Register: Classification of the Positive Airway Pressure Delivery System (21 CFR 868.5273), October 19, 2018
• FDA: Recalled Philips Ventilators, BiPAP Machines, and CPAP Machines — Consent Decree and Recommendations